# Determining the Optimal Dose of AD-211 in Patients With Osteoarthritis of the Knee

> **NCT07550231** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Addpharma Inc.** · enrollment: 200 (estimated)

## Conditions studied

- Osteoarthritis of the Knees

## Interventions

- **DRUG:** AD-211-L
- **DRUG:** AD-211-M
- **DRUG:** AD-211-H
- **DRUG:** AD-2113
- **DRUG:** Placebo to AD-211-L/M
- **DRUG:** Placebo to AD-211-H
- **DRUG:** Placebo to AD-2113

## Key facts

- **NCT ID:** NCT07550231
- **Lead sponsor:** Addpharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07550231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07550231, "Determining the Optimal Dose of AD-211 in Patients With Osteoarthritis of the Knee". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07550231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*